Skip to content

Viking Therapeutics, Inc.: 10-Q filed 2015-08-14

What Viking Therapeutics, Inc. reported in its quarterly report filed 2015-08-14 (fiscal Q2 2015): 22 published measures, 60 facts as tagged in accession 0001193125-15-291529.

This filing

Form
10-Q (quarterly report)
Filed
2015-08-14
Fiscal period
fiscal Q2 2015
Accession
0001193125-15-291529 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Viking Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-06-3022,269,649USD
At 2014-12-313,043,134USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-06-304,876,110USD
At 2014-12-3125,171,665USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-3017,393,539USD
At 2014-12-31-22,128,531USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-06-309,497,200USD
At 2014-12-31755,857USD
At 2014-06-30891,480USD
At 2013-12-31179,619USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-7,865,066USD91
2015-01-01 to 2015-06-30-13,576,481USD181
2014-04-01 to 2014-06-30-22,782,787USD91
2014-01-01 to 2014-06-30-23,011,729USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-04-01 to 2015-06-300USD91
2015-01-01 to 2015-06-300USD181
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-35,717,938USD
At 2014-12-31-22,141,457USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-06-301,472,412USD181
2014-01-01 to 2014-06-301,953USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-2,626,914USD91
2015-01-01 to 2015-06-30-3,087,954USD181
2014-04-01 to 2014-06-30-21,755,631USD91
2014-01-01 to 2014-06-30-21,965,369USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-3022,269,649USD
At 2014-12-31773,684USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-304,876,110USD
At 2014-12-3122,517,082USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-06-301,008,277USD
At 2014-12-311,830,724USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-04-01 to 2015-06-302,626,914USD91
2015-01-01 to 2015-06-303,087,954USD181
2014-04-01 to 2014-06-3021,755,631USD91
2014-01-01 to 2014-06-3021,965,369USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-301,100,906USD91
2015-01-01 to 2015-06-301,239,875USD181
2014-04-01 to 2014-06-3021,241,640USD91
2014-01-01 to 2014-06-3021,291,640USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-309,783,312shares
At 2014-12-316,000,000shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-12-31775USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-06-30610,198USD
At 2014-12-3117,827USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-7,877,527USD91
2015-01-01 to 2015-06-30-13,588,942USD181
2014-04-01 to 2014-06-30-22,782,787USD91
2014-01-01 to 2014-06-30-23,011,729USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-301,526,008USD91
2015-01-01 to 2015-06-301,848,079USD181
2014-04-01 to 2014-06-30513,991USD91
2014-01-01 to 2014-06-30673,729USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-5,238,152USD91
2015-01-01 to 2015-06-30-10,488,527USD181
2014-04-01 to 2014-06-30-1,027,156USD91
2014-01-01 to 2014-06-30-1,046,360USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-06-3025,392,500USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-06-3044,437USD181
2014-01-01 to 2014-06-30248,262USD181

Inspect the source

Entity
Viking Therapeutics, Inc. / CIK 0001607678
Captured
2026-09-20T09:26:18.703Z
SEC response SHA-256
c741f2f24971a4d10aa37b1e293b8d464b95b23c0fecb58db502cd6edd5b0617

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001607678.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))